Competing Interests Professor Melanie Davies has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for Abbvie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma Regeneron, GSK and EktaH and as a speaker for AstraZeneca and Boehringer Ingelheim
Hormonal shifts, insulin resistance, chronic stress, and muscle loss often make traditional approaches feel frustrating or ineffective
CA-3084004-C
References: Wilding JPH, et al
Semaglutide has strong phase 3 trial data, with that near-15% average backed by thousands of patients
And they will say, work with a provider who can help you with your hormones